Polycystic ovary syndrome

Keizo Ohnaka, Ryoichi Takayanagi

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by chronic unovulation, hyperandrogenism and polycystic change in ovary. Hyperinsulinemia is so often accompanied with PCOS that insulin resistance may play important roles in pathogenesis of PCOS. Recent studies reported the effectiveness of insulin-sensitizing drugs on treatment of patients with PCOS. Thiazolidinedione, an agonist of PPARgamma receptor, improves not only insulin sensitivity but also hyperandrogenism and ovulatory dysfunction in patients with PCOS. Insulin-sensitizing drugs such as thiazolidinediones are expected to be a novel therapy for PCOS, although further studies on the effectiveness and safety should be required.

Original languageEnglish
Pages (from-to)681-686
Number of pages6
JournalNippon rinsho. Japanese journal of clinical medicine
Volume63
Issue number4
Publication statusPublished - Apr 2005

Fingerprint

Polycystic Ovary Syndrome
Hyperandrogenism
Insulin Resistance
Insulin
Thiazolidinediones
PPAR gamma
Hyperinsulinism
Pharmaceutical Preparations
Ovary
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Polycystic ovary syndrome. / Ohnaka, Keizo; Takayanagi, Ryoichi.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 63, No. 4, 04.2005, p. 681-686.

Research output: Contribution to journalReview article

Ohnaka, Keizo ; Takayanagi, Ryoichi. / Polycystic ovary syndrome. In: Nippon rinsho. Japanese journal of clinical medicine. 2005 ; Vol. 63, No. 4. pp. 681-686.
@article{e7e691a6d7b14eefb8b392743105d24a,
title = "Polycystic ovary syndrome",
abstract = "Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by chronic unovulation, hyperandrogenism and polycystic change in ovary. Hyperinsulinemia is so often accompanied with PCOS that insulin resistance may play important roles in pathogenesis of PCOS. Recent studies reported the effectiveness of insulin-sensitizing drugs on treatment of patients with PCOS. Thiazolidinedione, an agonist of PPARgamma receptor, improves not only insulin sensitivity but also hyperandrogenism and ovulatory dysfunction in patients with PCOS. Insulin-sensitizing drugs such as thiazolidinediones are expected to be a novel therapy for PCOS, although further studies on the effectiveness and safety should be required.",
author = "Keizo Ohnaka and Ryoichi Takayanagi",
year = "2005",
month = "4",
language = "English",
volume = "63",
pages = "681--686",
journal = "Astrophysical Journal",
issn = "0004-637X",
publisher = "IOP Publishing Ltd.",
number = "4",

}

TY - JOUR

T1 - Polycystic ovary syndrome

AU - Ohnaka, Keizo

AU - Takayanagi, Ryoichi

PY - 2005/4

Y1 - 2005/4

N2 - Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by chronic unovulation, hyperandrogenism and polycystic change in ovary. Hyperinsulinemia is so often accompanied with PCOS that insulin resistance may play important roles in pathogenesis of PCOS. Recent studies reported the effectiveness of insulin-sensitizing drugs on treatment of patients with PCOS. Thiazolidinedione, an agonist of PPARgamma receptor, improves not only insulin sensitivity but also hyperandrogenism and ovulatory dysfunction in patients with PCOS. Insulin-sensitizing drugs such as thiazolidinediones are expected to be a novel therapy for PCOS, although further studies on the effectiveness and safety should be required.

AB - Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by chronic unovulation, hyperandrogenism and polycystic change in ovary. Hyperinsulinemia is so often accompanied with PCOS that insulin resistance may play important roles in pathogenesis of PCOS. Recent studies reported the effectiveness of insulin-sensitizing drugs on treatment of patients with PCOS. Thiazolidinedione, an agonist of PPARgamma receptor, improves not only insulin sensitivity but also hyperandrogenism and ovulatory dysfunction in patients with PCOS. Insulin-sensitizing drugs such as thiazolidinediones are expected to be a novel therapy for PCOS, although further studies on the effectiveness and safety should be required.

UR - http://www.scopus.com/inward/record.url?scp=18944361911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18944361911&partnerID=8YFLogxK

M3 - Review article

C2 - 15828237

AN - SCOPUS:18944361911

VL - 63

SP - 681

EP - 686

JO - Astrophysical Journal

JF - Astrophysical Journal

SN - 0004-637X

IS - 4

ER -